ALZHEIMER'S DISEASE & TAUOPATHY

Hyper-phosphorylation of Tau and aberrant gamma-secretase activity are respectively involved in the formation of intracellular neurofibrillary tangles and in the extracellular deposition of amyloid plaques in the brain – the two hallmarks of Alzheimers’s disease. Two in vitro pharmacological cell models are available at Fluofarma to identify or characterize compounds targeting Tau phosphorylation cascade or γ-secretase activity.

Fluofarma developed a proprietary biosensor based on a GFP-like reporter linked to C99 protein (beta-amyloid precursor), which is specifically cleaved by gamma-secretase. The resulting assay, optimized for high-throughput screening, is particularly suited for the selection of gamma-secretase inhibitors: